STOCK TITAN
  1. Home
  2. News
  3. PRQR

ProQR Therapeutics N.V - PRQR STOCK NEWS

Welcome to our dedicated news page for ProQR Therapeutics N.V (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on ProQR Therapeutics N.V.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProQR Therapeutics N.V's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProQR Therapeutics N.V's position in the market.

News
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
Rhea-AI Summary
ProQR Therapeutics NV. (Nasdaq: PRQR) announced the nomination of Martin Maier, PhD, to its Board of Directors and the upcoming Annual General Meeting of Shareholders on May 22, 2024. Dr. Maier, with extensive experience in RNA platforms and therapeutics, will bring valuable insights to the company. The AGM will also see a change in the Board structure to a one-tier system, with Dinko Valerio stepping down as chairperson. James Shannon, MD, will assume the role of chairperson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
News
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
Rhea-AI Summary
ProQR Therapeutics NV (Nasdaq: PRQR) announced new preclinical data for its Axiomer™ RNA editing technology platform at the ASGCT Annual Meeting. The company introduced the first preclinical data for its AX-0810 pipeline program targeting NTCP for cholestatic diseases. ProQR highlighted the robust editing efficiency of Axiomer editing oligonucleotides and the potential for cholestatic disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
News
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
Rhea-AI Summary
ProQR Therapeutics N.V. successfully defended its key patent for the Axiomer™ RNA editing platform against opposition filed in June 2021, maintaining its strong IP position. The European Patent Office ruled in favor of ProQR, protecting its chemically modified editing oligonucleotides that recruit endogenous ADAR for RNA editing. ProQR's extensive patent portfolio includes 28 patents and 15 published patent families, solidifying its leading position in ADAR-mediated RNA editing technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
News
ProQR Announces Year End 2023 Operating and Financial Results
Rhea-AI Summary
ProQR Therapeutics NV (PRQR) reported financial results for 2023, highlighting progress in RNA editing technology. The company strengthened its IP estate, formed partnerships, and divested ophthalmic assets. ProQR anticipates sharing pipeline program data in 2024 and entering the clinic by late 2024/early 2025. The company holds €118.9 million in cash, providing runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.66%
Tags
earnings
-
News
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
Rhea-AI Summary
ProQR Therapeutics N.V. announced the successful defense of its patent in Japan for its ADAR-mediated RNA editing platform Axiomer™. The Japanese Patent Office rejected the opposition, maintaining all claims as granted to ProQR. The company's strong IP position in RNA editing using oligonucleotides and endogenous ADAR is further reinforced by this decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
News
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
Rhea-AI Summary
ProQR Therapeutics NV highlights robust in vivo editing capabilities of its Axiomer RNA editing technology platform, demonstrating up to 70% editing of ACTB in the liver of non-human primates and mice. Functional effect demonstrated in mice via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkers. Additional data to be presented in 2024 for pipeline programs targeting Cholestatic diseases and Cardiovascular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
News
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
Rhea-AI Summary
ProQR Therapeutics NV (Nasdaq: PRQR) announced a collaboration with the Rett Syndrome Research Trust (RSRT) to develop editing oligonucleotides targeting the transcription factor MECP2 using its proprietary Axiomer™ RNA editing technology platform. The collaboration aims to address the unmet medical need in Rett syndrome, a rare neurodevelopmental disorder. RSRT awarded ProQR approximately $1 million as a research grant for the initial phase of the project, with the potential for expanded co-funding for clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
Rhea-AI Summary
ProQR Therapeutics N.V. (Nasdaq: PRQR) has completed the divestment of late stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Théa (Théa). Théa will continue the development of these potentially transformational therapies for patients with LCA10 and Usher Syndrome. ProQR received an initial payment of €8M and may be eligible for up to €165M in further development, regulatory, and commercial earn-out payments, as well as double-digit royalties based on commercial sales in the US and EU. The company is now focusing on advancing its Axiomer RNA editing platform for targets in cholestatic and cardiovascular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
acquisition
-
News
ProQR Announces Third Quarter 2023 Operating and Financial Results
Rhea-AI Summary
ProQR Therapeutics NV. (Nasdaq: PRQR) reported €120.6M in cash and cash equivalents as of September 30, 2023, providing runway into mid-2026. The company continues to advance AX-0810 for cholestatic diseases and AX-1412 for cardiovascular risk, with upcoming pipeline program data releases. ProQR also announced strengthening of its IP position with new patents in the US and successful defense against opposition in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.66%
Tags
earnings
News
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
Rhea-AI Summary
ProQR Therapeutics has strengthened its intellectual property estate with the issuance of a new patent in the United States and successfully defended against an opposition to its IP in Japan. The new patent expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR, further solidifying ProQR's leading IP position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Stock PRQR logo
ProQR Therapeutics N.V

Nasdaq:PRQR

PRQR Rankings

#3949 Ranked by Market Cap
#725 Ranked by Stock Gains
N/A Ranked by Dividends

PRQR Stock Data

178.98M
57.49M
18.87%
40.33%
0.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Leiden

About PRQR

proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com